Exagen Inc. (XGN) - Form 8-K Summary
Business Context and Reporting Period
Company: Exagen Inc.
Filing Date: October 21, 2021 (Event Date)
Reporting Period: Current Report regarding a material definitive agreement entered into on October 21, 2021, effective November 1, 2021.
Context: The Company is an emerging growth company incorporated in Delaware, trading on the Nasdaq Global Market under the symbol XGN.
Key Financial Metrics and Debt Structure
This filing details a refinancing of the Company's term loan agreement with Innovatus Life Sciences Lending I, LP and other lenders. The filing does not provide specific revenue, profit, cash flow, or liquidity figures for the period.
- Interest Rate: Decreased to 8.0% on all borrowings.
- Payment Structure: 2.0% of the interest will be paid in-kind (PIK) and capitalized to the principal monthly until December 1, 2024. The remaining 6.0% is presumably cash interest, though the text specifies the total rate is 8.0% with 2.0% PIK.
- Interest-Only Period: Extended through December 2024.
- Maturity Date: Extended to November 19, 2026.
- Financial Covenants: The specified revenue level required to satisfy financial covenants has been modified. This applies to rolling twelve-month periods commencing with the quarter ending December 31, 2022.
Material Changes Versus Prior Period
The Second Amendment to the Loan and Security Agreement represents a material change to the Company's debt obligations compared to the Original Loan Agreement (dated September 7, 2017, as amended November 19, 2019). Key changes include:
- Reduction in the interest rate.
- Introduction of a 2.0% PIK component until late 2024.
- Extension of the interest-only period and overall loan maturity.
- Adjustment to revenue-based financial covenants with provisions for curing defaults via equity issuance or subordinated indebtedness.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on October 25, 2021, announcing the refinancing. The amendment is designed to provide flexibility through extended maturity and modified covenants.
Risks and Contingencies:
- Covenant Compliance: The Company must achieve specific revenue levels starting with the quarter ending December 31, 2022, to satisfy financial covenants.
- Default Cure: Defaults may be cured through the issuance of equity securities or subordinated indebtedness, which could result in dilution to existing shareholders.
- Capitalization: The PIK interest will increase the principal balance of the outstanding term loan until December 2024.
Investor Verification Checklist
- Verify the exact terms of the revenue covenants for the quarter ending December 31, 2022, in the upcoming Form 10-Q.
- Review the full text of the Second Loan Amendment (to be filed as an exhibit to the Q3 2021 10-Q) for details on the "specified level of revenue."
- Monitor the Company's ability to meet the modified covenants to avoid potential default scenarios requiring equity issuance.
- Assess the impact of the 2.0% PIK interest on the total debt principal balance over the next three years.